---
document_datetime: 2023-09-21 21:19:28
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zalviso-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zalviso-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7994586
conversion_datetime: 2025-12-28 10:53:32.025395
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zalviso

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on Product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                           |
|----------------------|-----------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------|
| T/0017               | Transfer of Marketing Authorisation     | 06/08/2021                                  | 29/09/2021                                  | SmPC, Labelling and PL           |                                                                                                                   |
| R/0016               | Renewal of the marketing authorisation. | 23/07/2020                                  | 24/09/2020                                  | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of |

Medicinal Product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                   |            |               |             | Zalviso in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0015/G          | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer | 27/01/2020 | n/a           | longer      | authorised                                                                                                                                            |
| WS/1719            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Product                                                                                                                                           | 16/01/2020 | 24/09/2020 no | SmPC and PL |                                                                                                                                                       |
| PSUSA/2798/ 201811 | Periodic Safety Update EU Single assessment - sufentanil                                                                                                                                                                                                                                                                                                                                                          | 25/07/2019 | 01/10/2019    | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2798/201811.             |
| IB/0011            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation Medicinal                                                                                                                                                                                                                                                                                                          | 23/07/2019 | 01/10/2019    | SmPC and PL |                                                                                                                                                       |
| IA/0010            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the                                                                                                                                                                                                                                                                                                               | 27/11/2018 | n/a           |             |                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                          | authorised   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------|
| IA/0009/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 27/11/2018 n/a           | longer       |
| N/0008    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 22/05/2017 01/10/2019 no | Labelling    |
| IB/0007   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation Product                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/05/2017 n/a n/a       |              |
| IA/0003/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure Medicinal                                                                                                                                                                                                                                                       | 11/01/2017               |              |

<div style=\"page-break-after: always\"></div>

| IB/0006            | B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test   | 04/01/2017   | n/a                |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------|-----------------------------------|
| IB/0005            | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                     | 04/01/2017   | n/a                | authorised                        |
| IB/0004            | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                     | 04/01/2017   | n/a                |                                   |
| PSUSA/2798/ 201511 | Periodic Safety Update EU Single assessment - sufentanil                                                                                                   | 02/09/2016   | n/a longer         | PRAC Recommendation - maintenance |
| IA/0002            | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                              | 27/04/2016   | 06/04/2017 SmPC no |                                   |

Medicinal Product no longer authorised